

# Arjan Diepstra

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2030747/arjan-diepstra-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119 papers	3,081 citations	29 h-index	53 g-index
128 ext. papers	3,717 ext. citations	5.7 avg, IF	4.67 L-index

#	Paper	IF	Citations
119	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2022</b> , 480, 667	5.1	3
118	CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma.. <i>OncolImmunology</i> , <b>2022</b> , 11, 2033433	7.2	0
117	Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 829943	8.4	1
116	A Rare Case of Epstein-Barr Virus-Positive T-Cell Lymphoma in the Skin of an Immunocompromised Patient.. <i>American Journal of Dermatopathology</i> , <b>2022</b> , 44, e19-e22	0.9	0
115	Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 845301	8.4	0
114	Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer. <i>Cancers</i> , <b>2022</b> , 14, 2397	6.6	1
113	Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment. <i>Annals of Hematology</i> , <b>2021</b> ,	3	1
112	Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome. <i>Blood</i> , <b>2021</b> , 138, 1331-1331	2.2	
111	Gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. <i>Blood</i> , <b>2021</b> ,	2.2	1
110	Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-year Prospective Cohort Study. <i>Transplantation</i> , <b>2021</b> , 105, 1106-1115	1.8	1
109	Non-small-cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy. <i>Histopathology</i> , <b>2021</b> , 78, 1043-1046	7.3	1
108	Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing. <i>Nature Communications</i> , <b>2021</b> , 12, 3361	17.4	0
107	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 4369-4376	8.8	4
106	Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , <b>2021</b> , 106, 1129-1137	6.6	19
105	Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
104	Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment. <i>HemaSphere</i> , <b>2021</b> , 5, e523	0.3	2
103	Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 506-514	4.5	1

102	Genetically Raised Circulating Bilirubin Levels and Risk of Ten Cancers: A Mendelian Randomization Study. <i>Cells</i> , <b>2021</b> , 10,	7.9	2
101	Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality. <i>Blood Advances</i> , <b>2021</b> , 5, 3266-3278	7.8	0
100	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. <i>Blood Advances</i> , <b>2021</b> , 5, 3760-3775	7.8	3
99	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAH trial. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	1
98	Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [F]FDG PET/CT. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
97	Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing.. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-5	1.9	0
96	Molecular imaging in lymphoma beyond F-FDG-PET: understanding the biology and its implications for diagnostics and therapy. <i>Lancet Haematology</i> , <b>2020</b> , 7, e479-e489	14.6	5
95	Interim thymus and activation regulated chemokine versus interim F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 40-44	4.5	9
94	Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. <i>Haematologica</i> , <b>2020</b> , 105, 2805-2812	6.6	10
93	F-FDG PET/CT in the Diagnostic and Treatment Evaluation of Pediatric Posttransplant Lymphoproliferative Disorders. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1307-1313	8.9	8
92	Microenvironment, Cross-Talk, and Immune Escape Mechanisms. <i>Hematologic Malignancies</i> , <b>2020</b> , 69-86	0	
91	Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 82, 101931	14.4	20
90	Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58. <i>Blood</i> , <b>2020</b> , 136, 2437-2441	2.2	10
89	Biopsy-Controlled Non-Invasive Quantification of Collagen Type VI in Kidney Transplant Recipients: A Post-Hoc Analysis of the MECANO Trial. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
88	Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis. <i>Blood Advances</i> , <b>2020</b> , 4, 6353-6363	7.8	13
87	Tumour necrosis as assessed with F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements. <i>European Radiology</i> , <b>2019</b> , 29, 6018-6028	8	3
86	Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment. <i>Haematologica</i> , <b>2019</b> , 104, e21-e24	6.6	13
85	CD27CD38 B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2221	8.4	17

84	Complement activation and long-term graft function in ABO-incompatible kidney transplantation. <i>World Journal of Nephrology</i> , <b>2019</b> , 8, 95-108	3.6	3
83	High Frequencies of Mutated EZH2 and IRF8 and Other Epigenetic Genes in Primary Bone Lymphomas Are Indicative of GCB-Phenotype. <i>Blood</i> , <b>2019</b> , 134, 1484-1484	2.2	
82	Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 83	8.4	19
81	Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment. <i>Haematologica</i> , <b>2019</b> , 104, e45-e46	6.6	2
80	Argonaute 2 RNA Immunoprecipitation Reveals Distinct miRNA Targetomes of Primary Burkitt Lymphoma Tumors and Normal B Cells. <i>American Journal of Pathology</i> , <b>2018</b> , 188, 1289-1299	5.8	4
79	Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. <i>Blood</i> , <b>2018</b> , 131, 2036-2046	2.2	24
78	High prevalence of and mutations in intravascular large B-cell lymphoma. <i>Blood</i> , <b>2018</b> , 131, 2086-2089	2.2	36
77	Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma. <i>Annals of Hematology</i> , <b>2018</b> , 97, 905-907	3	2
76	Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. <i>Melanoma Research</i> , <b>2018</b> , 28, 96-104	3.3	30
75	Targeting the Microenvironment in Hodgkin Lymphoma: Opportunities and Challenges. <i>Molecular Pathology Library</i> , <b>2018</b> , 59-90		
74	Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, e16	2.4	6
73	Relapse in stage I(E) diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , <b>2018</b> , 36, 416-421	1.3	5
72	The Microenvironment in Epstein-Barr Virus-Associated Malignancies. <i>Pathogens</i> , <b>2018</b> , 7,	4.5	29
71	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , <b>2018</b> , 132, 998-998	2.2	8
70	Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. <i>PLoS ONE</i> , <b>2018</b> , 13, e0193098	3.7	14
69	Combined loss of HLA I and HLA II expression is more common in the non-GCB type of diffuse large B cell lymphoma. <i>Histopathology</i> , <b>2018</b> , 72, 886-888	7.3	3
68	Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , <b>2018</b> , 10,	6.6	9
67	MicroRNA High Throughput Loss-of-Function Screening Reveals an Oncogenic Role for miR-21-5p in Hodgkin Lymphoma. <i>Cellular Physiology and Biochemistry</i> , <b>2018</b> , 49, 144-159	3.9	17

66	Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones. <i>Cancer Cell</i> , <b>2018</b> , 34, 674-689.e8	24.3	45
65	Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment. <i>Histopathology</i> , <b>2018</b> , 73, 473-482	7.3	4
64	Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity. <i>Pediatric Nephrology</i> , <b>2017</b> , 32, 733-741	3.2	56
63	miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 1343-1355	5.8	32
62	HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. <i>Onc Immunology</i> , <b>2017</b> , 6, e1295202	7.2	60
61	High human cytomegalovirus DNAemia early post-transplantation associates with irreversible and progressive loss of renal function - a retrospective study. <i>Transplant International</i> , <b>2017</b> , 30, 817-826	3	7
60	Kidney Involvement in Systemic Calcitonin Amyloidosis Associated With Medullary Thyroid Carcinoma. <i>American Journal of Kidney Diseases</i> , <b>2017</b> , 69, 546-549	7.4	7
59	Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3722-3733	2.2	29
58	Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 810-812	4.5	6
57	Lymphadenopathy driven by TCR-V8V1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome. <i>Blood Advances</i> , <b>2017</b> , 1, 1101-1106	7.8	2
56	Human alternative Klotho mRNA is a nonsense-mediated mRNA decay target inefficiently spliced in renal disease. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	39
55	HLA expression and HLA type associations in relation to EBV status in Hispanic Hodgkin lymphoma patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0174457	3.7	6
54	A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0178801	3.7	12
53	Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas. <i>PLoS ONE</i> , <b>2016</b> , 11, e0146624	3.7	5
52	Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma. <i>Oncotarget</i> , <b>2016</b> , 7, 2391-400	3.3	34
51	Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	9
50	Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 868-875	4.5	27
49	Long Noncoding RNA Expression Profiling in Normal B-Cell Subsets and Hodgkin Lymphoma Reveals Hodgkin and Reed-Sternberg Cell-Specific Long Noncoding RNAs. <i>American Journal of Pathology</i> , <b>2016</b> , 186, 2462-72	5.8	27

48	Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a <i>Haemophilus influenzae</i> -driven immune disorder?. <i>Journal of Pathology</i> , <b>2015</b> , 236, 302-14	9.4	18
47	CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma. <i>Experimental Hematology and Oncology</i> , <b>2015</b> , 4, 27	7.8	11
46	Microenvironment, Crosstalk, and Immune Escape Mechanisms. <i>Hematologic Malignancies</i> , <b>2015</b> , 65-78	o	
45	A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 1838-43	4	16
44	Long noncoding RNAs as a novel component of the Myc transcriptional network. <i>FASEB Journal</i> , <b>2015</b> , 29, 2338-46	0.9	42
43	The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. <i>Seminars in Cancer Biology</i> , <b>2014</b> , 24, 15-22	12.7	79
42	Genetic associations in classical hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2737-47	4	30
41	Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e87474	3.7	19
40	The Role of MicroRNAs in Hodgkin's Lymphoma <b>2013</b> , 435-447		
39	PML nuclear bodies and SATB1 are associated with HLA class I expression in EBV+ Hodgkin lymphoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e72930	3.7	5
38	Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 240-53	9.7	117
37	HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China. <i>PLoS ONE</i> , <b>2012</b> , 7, e31865	3.7	22
36	HLA associations in classical Hodgkin lymphoma: EBV status matters. <i>PLoS ONE</i> , <b>2012</b> , 7, e39986	3.7	41
35	Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. <i>Blood</i> , <b>2012</b> , 120, 3530-40	2.2	100
34	Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. <i>Haematologica</i> , <b>2012</b> , 97, 410-5	6.6	45
33	Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. <i>Haematologica</i> , <b>2012</b> , 97, 572-8	6.6	26
32	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. <i>Nature</i> , <b>2011</b> , 471, 377-81	50.4	467
31	MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. <i>Journal of Pathology</i> , <b>2011</b> , 225, 609-17	9.4	29

30	Epidemiology of classical Hodgkin lymphoma and its association with Epstein Barr virus in Northern China. <i>PLoS ONE</i> , <b>2011</b> , 6, e21152	3.7	21
29	Microenvironment, Cross-Talk, and Immune Escape Mechanisms <b>2011</b> , 49-61		1
28	CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome. <i>Blood</i> , <b>2011</b> , 118, 427-427	2.2	
27	EBV and HLA Associations In Classical Hodgkin Lymphoma Patients From Brazil. <i>Blood</i> , <b>2011</b> , 118, 4858-4858		
26	A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). <i>Nature Genetics</i> , <b>2010</b> , 42, 1126-1130	36.3	158
25	Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 539-41	7.1	20
24	Mid-Treatment Plasma Levels of Thymus Activated and Regulated Chemokine (TARC) Predict Treatment Outcome In Classical Hodgkin Lymphoma Patients. <i>Blood</i> , <b>2010</b> , 116, 748-748	2.2	1
23	Expression of HLA class I and HLA class II by tumor cells in Chinese classical Hodgkin lymphoma patients. <i>PLoS ONE</i> , <b>2010</b> , 5, e10865	3.7	15
22	HLA Class I and EBV Positive Classical Hodgkin Lymphoma In the Chinese Population. <i>Blood</i> , <b>2010</b> , 116, 2688-2688	2.2	
21	Protective and Predisposing HLA Alleles In Dutch Classical Hodgkin Lymphoma Patients. <i>Blood</i> , <b>2010</b> , 116, 749-749	2.2	
20	MHC class II as a therapeutic target in B-cell lymphomas: the CIITA road to paradise?. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 1740-1	1.9	2
19	Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3815-21	2.2	71
18	miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. <i>Laboratory Investigation</i> , <b>2009</b> , 89, 708-16	5.9	87
17	Expression of CD1c, CD1d and Presence of Invariant NKT Cells in Hodgkin Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 3659-3659	2.2	
16	The HGF/c-Met Signaling Pathway in Hodgkin Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 1551-1551	2.2	
15	Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. <i>British Journal of Haematology</i> , <b>2008</b> , 140, 527-36	4.5	93
14	Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. <i>Blood</i> , <b>2008</b> , 111, 2339-46	2.2	99
13	Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma. <i>Hematological Oncology</i> , <b>2007</b> , 25, 21-9	1.3	21



12	HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3101-8	2.2	107
11	HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. <i>Blood</i> , <b>2007</b> , 110, 3310-5	2.2	111
10	The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 2280-4	4	32
9	Polymorphisms and Lack of or Aberrant Expression of HLA Class I and II May Influence Antigen Presentation in Classical Hodgkin Lymphoma.. <i>Blood</i> , <b>2005</b> , 106, 20-20	2.2	1
8	Haplotype-Based Sequencing To Delineate the Associated HLA Class I Region for EBV Positive Hodgkin Lymphoma.. <i>Blood</i> , <b>2005</b> , 106, 971-971	2.2	
7	Population Based Genotyping of Human Leukocyte Antigen (HLA) in Hodgkin Lymphoma: EBV Positive HL Is Associated with HLA Class I and EBV Negative HL Is Associated with HLA Class III.. <i>Blood</i> , <b>2004</b> , 104, 432-432	2.2	
6	Immune Dysfunction in Classical Hodgkin's Lymphoma <b>2004</b> , 315-334		2
5	High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. <i>Genes Chromosomes and Cancer</i> , <b>2003</b> , 37, 20-8	5	208
4	Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma. <i>American Journal of Pathology</i> , <b>2003</b> , 162, 29-35	5.8	50
3	Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. <i>International Journal of Cancer</i> , <b>2002</b> , 99, 665-72	7.5	56
2	Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma. <i>Blood</i> , <b>2002</b> , 100, 1425-1429	2.2	67
1	Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma. <i>Blood</i> , <b>2002</b> , 100, 1425-9	2.2	15